TrialTargeted oncology2020

Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer.

Todd M Bauer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.